| 000 | 01778 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250514161857.0 | ||
| 264 | 0 | _c20040309 | |
| 008 | 200403s 0 0 eng d | ||
| 022 | _a0344-5704 | ||
| 024 | 7 |
_a10.1007/s00280-003-0722-9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBolton, Ann E | |
| 245 | 0 | 0 |
_aEffect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. _h[electronic resource] |
| 260 |
_bCancer chemotherapy and pharmacology _cFeb 2004 |
||
| 300 |
_a102-6 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibiotics, Antitubercular _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 |
_aAryl Hydrocarbon Hydroxylases _xbiosynthesis |
| 650 | 0 | 4 | _aBenzamides |
| 650 | 0 | 4 | _aBiotransformation |
| 650 | 0 | 4 | _aCytochrome P-450 CYP3A |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aEnzyme Induction _xdrug effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydrocortisone _xblood |
| 650 | 0 | 4 | _aImatinib Mesylate |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aOxidoreductases, N-Demethylating _xbiosynthesis |
| 650 | 0 | 4 |
_aPiperazines _xadverse effects |
| 650 | 0 | 4 |
_aPyrimidines _xadverse effects |
| 650 | 0 | 4 |
_aRifampin _xadverse effects |
| 700 | 1 | _aPeng, Bin | |
| 700 | 1 | _aHubert, Martine | |
| 700 | 1 | _aKrebs-Brown, Axel | |
| 700 | 1 | _aCapdeville, Renaud | |
| 700 | 1 | _aKeller, Urs | |
| 700 | 1 | _aSeiberling, Michael | |
| 773 | 0 |
_tCancer chemotherapy and pharmacology _gvol. 53 _gno. 2 _gp. 102-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00280-003-0722-9 _zAvailable from publisher's website |
| 999 |
_c14343480 _d14343480 |
||